CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway

BACKGROUND: In colorectal cancer, CDX2 expression is lost in approximately 20% of cases and associated with poor outcome. Here, we aim to validate the clinical impact of CDX2 and investigate the role of promoter methylation and histone deacetylation in CDX2 repression and restoration. METHODS: CDX2...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Epigenetics
Auteurs principaux: Graule, Janina, Uth, Kristin, Fischer, Elia, Centeno, Irene, Galván, José A., Eichmann, Micha, Rau, Tilman T., Langer, Rupert, Dawson, Heather, Nitsche, Ulrich, Traeger, Peter, Berger, Martin D., Schnüriger, Beat, Hädrich, Marion, Studer, Peter, Inderbitzin, Daniel, Lugli, Alessandro, Tschan, Mario P., Zlobec, Inti
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2018
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6158822/
https://ncbi.nlm.nih.gov/pubmed/30257705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-018-0548-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires